ACV meeting statement, Meeting 42, 12 April 2023

Section A: Submissions for registration

The committee provided advice on the submission to transition SPIKEVAX COVID-19 vaccine, containing elasomeran (sponsor Moderna Australia Pty Ltd), from provisional registration to full registration for use in individuals 6 years of age and older.

Details of the ACV advice has been or will be released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see Australian Public Assessment Reports (AusPAR).

Section B: Post-market items

The ACV was not asked to provide advice on a post-market or safety issue.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines (ACV).

or contact the ACV by email ACV@health.gov.au.